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Protein aggregation likely plays a key role in the initiation and spreading of Alzheimer’s disease pathology through the brain.
Soluble aggregates of amyloid beta are believed to play a key role in this process. However, the aggregates present in humans are
still poorly characterized due to a lack of suitable methods required for characterizing the low concentration of heterogeneous
aggregates present. We have used a variety of biophysical methods to characterize the aggregates present in human Alzheimer’s dis-
ease brains at Braak stage III. We find soluble amyloid beta-containing aggregates in all regions of the brain up to 200 nm in
length, capable of causing an inflammatory response. Rather than aggregates spreading through the brain as disease progresses, it
appears that aggregation occurs all over the brain and that different brain regions are at earlier or later stages of the same process,
with the later stages causing increased inflammation.
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Introduction
Alzheimer’s disease is a progressive neurodegenerative dis-
ease characterized by memory loss and cognitive decline.
It is the leading cause of dementia, which is currently the
leading cause of death in the UK.1 The aggregation of
the amyloid beta 42 peptide (Ab42) is believed to play a
key role in the initiation and development of the disease.2
It is widely accepted that small soluble Ab42 aggregates
are toxic, likely through a variety of mechanisms, includ-
ing the permeabilization of cell membranes through non-
specific binding and by specific binding to pattern-recog-
nizing membrane receptors.3–6 This can lead to microglial
activation and inflammation,7 a key player in Alzheimer’s
disease pathology.6,8,9 Microglial activation increases as
the disease progresses, and they become dystrophic at
late stages.10 Activated microglia have been shown to in-
duce astrocytes into releasing neurotoxic factors.11
Through these toxic mechanisms, Ab42 aggregates have
been shown to cause neuronal cell death, synaptic dys-
function, as well as cognitive impairment in Alzheimer’s
disease patients and animal models of the disease.12–22
Despite only being a small subset of the overall protein
aggregates found in brain tissue, it is believed that the
soluble aggregates are responsible for most of the tox-
icity.23 This is supported by the fact that insoluble amyl-
oid plaque counts do not correlate well with cognitive
function,24–27 and soluble Ab levels correlate better with
cognition than insoluble Ab levels.28–32 Soluble aggregates
have been found in the brain lysates of Alzheimer’s
disease patients.33–35 However, these soluble aggregates
occur at low concentrations and hence have been poorly
characterized due to a lack of sensitive methods, with
many more studies performed on aggregates formed from
synthetic Ab42, since they are available in higher concen-
trations.36 It is still unclear how comparable endogenous
aggregates from Alzheimer’s disease patients are to syn-
thetic aggregates or to those from animal models.37,38
Far less research has been done on the aggregates in
human CSF or extracted from post-mortem brain. Brain
samples are generally homogenized and hence include
large amounts of insoluble aggregates, which are largely
inert, as well as soluble aggregates potentially complicat-
ing the interpretation of any analysis.
To address these issues, there has been a recent effort
to selectively extract the soluble aggregates from human
brain tissue using minimally perturbative methods.23,39
We have developed a suite of sensitive methods with the
potential to characterize aggregates and measure their
properties.7 These include correlating changes in the ag-
gregate size distribution with changes in the mechanism
of toxicity as demonstrated by experiments on CSF from
Alzheimer’s disease patients.40 In the literature, soluble
aggregates from Braak stage VI AD brain have been
found to contain Ab42 aggregates as identified through
western blotting and ELISAs. These samples have also
been shown to cause neurite length retraction on iPSC-
derived neurons, and can block synaptic long-term po-
tentiation.23,41 Furthermore, they induce neuronal hyper-
activation in mouse CA1 hippocampal neurons, as seen
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with two photon Ca2þ imaging.42,43 Toxicity caused by
soluble aggregates is believed to be mediated partly by
prion protein.44 Experiments have shown that soluble
aggregates extracted from soaking brain tissue are as
toxic as homogenized brain samples but contain signifi-
cantly less Ab42 aggregates making them an ideal sample
for characterization. This toxicity appears to be Ab-de-
pendent, as evidenced by Ab-immunodepleted samples
being significantly less toxic.23 However, there is no in-
formation about the size or structure of these aggregates
extracted by soaking post-mortem brain nor how the
aggregates differ between different brain regions.
Alzheimer’s disease has a typical pathological progres-
sion, starting in the hippocampal/entorhinal cortex
regions and spreading to the temporal, parietal and front-
al lobes before affecting the occipital lobe.45,46 For our
initial experiments, we decided to study soluble aggre-
gates from Braak stage III, which is at the early stages of
pathological progression and therefore before the appear-
ance of global pathology, to assess regional variability be-
tween different regions of the same patient and between
patients.47,48 After establishing that our assays have suffi-
cient sensitivity to detect the aggregates present, we char-
acterized the soluble aggregates from eight brain regions,
from three Alzheimer’s disease patients. We then chose to
compare in more detail the soluble aggregates from two
distinct regions, the hippocampus (HPC), which is signifi-
cantly affected early in the disease, and the visual associ-
ation cortex (VAC), a region affected later in the disease,
with the latter acting as an internal control for each
brain.
In this pilot study, we applied our methods (Fig. 1) to
characterize soluble aggregates from Braak stage III
(Table 1). We have identified the similarities and differen-
ces between the soluble aggregates in eight different
regions by providing a detailed characterization of their
size, morphology, structure, neurotoxicity, inflammatory
potential and capability to permeabilize a lipid mem-
brane. These data show that soluble aggregates of a
range of sizes and morphologies, capable of causing in-
flammation, are already present in all brain regions at
Braak stage III and that aggregation is occurring by the
same processes all over the brain to a greater or lesser
extent.
Materials and methods
Alzheimer’s disease brain tissue
Fresh frozen brains from three Alzheimer’s disease
patients (Table 1) were received whole from the
Addenbrooke’s post-mortem room, or from other centres
around the country. Transport and consent details were
reviewed and handled by the Cambridge Brain Bank.
Processing of tissue was carried out in Addenbrooke’s
hospital, where regions of interest were removed from
the left cerebral hemisphere and frozen at 80C. The
brains used for the following experiments were diagnosed
as being at Braak stage III by histopathologists, based on
tau protein pathology.
Extraction of soluble aggregates
from human brain tissue
Soluble aggregates were obtained by following a previ-
ously established protocol with a few adaptations.23
Briefly, human brain tissue was chopped into 300 mg
pieces using a razor blade and incubated with gentle agi-
tation in 1.5 ml of artificial cerebrospinal fluid (aCSF)
buffer (124 mM NaCl, 2.8 mM KCl, 1.25 mM NaH2PO4,
26 mM NaHCO3; pH 7.4, supplemented with 5 mM
EDTA, 1 mM EGTA, 5 lg/ml leupeptin, 5 lg/ml aprotinin,
2 lg/ml pepstatin, 20 lg/ml Pefabloc, 5 mM NaF) at 4C
for 30 min. Samples were centrifuged at 2000 g at 4C
for 10 min and the upper 90% of the supernatant was
collected and centrifuged at 14 000 g for 110 min at 4C.
The upper 90% of the supernatant was extracted and
dialyzed using Slide-A-LyzerTM cassettes (Thermo
Scientific, Cat. 66330) with a 2 kDa molecular weight cut
off, against 100-fold excess of fresh aCSF buffer with
gentle agitation at 4C. Buffer was changed three times
over the course of 72 h dialysis. The prep was carried
out under sterile conditions, using autoclaved LoBind
Eppendorf tubes and pre-sterilized pipette tips to reduce
endotoxin contamination. Samples were aliquoted into
small volumes, snap frozen and stored in a 80C freezer
and thawed only once prior to experimentation.
Neuroinflammation assay
BV-2 cells derived from immortalized murine neonatal
microglia (European Collection of Authenticated Cell
Cultures) were grown in T25 flasks in Dulbecco’s modi-
fied eagle medium (DMEM) (Gibco, Life Technologies,
Cat. 21063-029) with 10% (v/v) foetal bovine serum
(FBS) (Sigma-Aldrich, St. Louis, MO, Cat. F0926), 100 U/
ml penicillin/100 lg/ml streptomycin (Gibco, Life
Technologies, Cat. 15140-122), 2 mM L-glutamine
(Gibco, Life Technologies, Cat. 25030-024), 1% (v/v) so-
dium pyruvate and 1% (v/v) HEPES buffer. They were
grown in a humidified environment, incubated at 37C,
with 5% CO2, 95% air. Cells were plated in flat-bottom
96-well plates (Corning, Costar, Cat. CLS3997) in
DMEM 10% (v/v) FBS at a concentration of 1.65  105
cells/ml (150 ll per well). Twenty-four hours after plating,
the cells were washed with fresh pre-warmed (37C)
media and kept in phenol red-containing DMEM 1% (v/
v) FBS. Cells were treated with soluble aggregates in a
1:5 dilution. Lipopolysaccharide (Invivogen San Diego,
CA, Cat. Tlrl-3pelps) at 10 ng/ml was used as a positive
control and aCSF buffer in a 1:5 dilution was used as a
negative control. The supernatant was collected every
24 h for analysis and the wells were washed with fresh
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Figure 1 Schematics of assays used to characterize soluble aggregates. (A) Extraction of soluble aggregates from human brain tissue
through soaking in aCSF. (B) Neuroinflammation assay using BV2 cells to measure production of TNF-a. (C) Liposome assay used to measure
the aggregates’ ability to penetrate a lipid membrane. (D) Neurite length assay used to measure neurotoxicity. (E) Single-molecule pull-down
imaging used for the characterization of Ab-containing aggregates. (F) Aptamer DNA-PAINT imaging used to characterize the size and number
of aggregates. (G) AFM imaging of 3D morphology used to characterize morphology and cross-sectional dimensions of the aggregates. aCSF,
artificial cerebrospinal fluid; TNF-a, tumour necrosis factor-a, ELISA, enzyme-linked immunosorbent assay; TIRF, total internal reflection
fluorescence.
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media and replaced with fresh solution. The supernatant
was stored in a 80C freezer and thawed only once be-
fore being measured with a mouse TNF-a DuoSet ELISA
(R&D Systems, MN, USA, Cat. DY410) using a plate
reader (CLARIOstar, BMG Labtech, Ortenberg,
Germany) at 450 nm. Experiments were carried out over
96–120 h. Three wells were used for each sample of sol-
uble aggregates to estimate variation.
Cytotoxicity assay
Cell supernatant collected from the neuroinflammatory
assay was stored at 80C. A lactate dehydrogenase
(LDH) assay (Abcam, Colorimetric, Cat. ab102526) was
used to detect the concentration of LDH (mU/ml) in the
supernatants. Cells treated with RIPA lysis buffer
(Thermo Scientific, Cat. 89900) were taken as complete
cell death (100%), whereas cells of the same density
treated with aCSF buffer were taken as healthy cells
(0%). The supernatants were thawed only once before
taking measurements.
Immunoprecipitation experiments
Immunoprecipitation was carried out as described previ-
ously, with a few modifications.49 Briefly, DynabeadsV
R
Protein A (Invitrogen, Cat. 10002D) and DynabeadsV
R
Protein G (Invitrogen, Cat. 10004D), mixed in a 1:1
ratio in low-binding snap top tubes (Eppendorf AG,
Hamburg, Germany), were used to bind and pull down
an APP-binding antibody (6E10, Mouse IgG1, Biolegend,
Cat. SIG-39320). The antibody was added at a concen-
tration of 20 lg/ml. Four hundred microlitres of soluble
aggregates from the HPC and VAC regions were then
added to the mix. The snap top tubes were placed on a
magnetic rack to pull down the magnetic beads, along
with the antibody and binding targets. The neuroinflam-
mation assay was then carried out on samples of soluble
aggregates with or without immunodepletion of Ab-con-
taining fragments.
Neurite length assay
Lund Human Mesencephalic (LUHMES) cells were pur-
chased from the American Type Culture Collection
(ATCC) (Cat. CRL-2927) and were cultured according to
the ATCC guidelines. Briefly, the cells were grown in a
T75 flask pre-coated with 50 lg/ml poly-L-ornithine
(Sigma, Cat. P3655) and 1 lg/ml Human Fibronectin
(Sigma, Cat. F-0895) in DMEM: F12 (Invitrogen, Cat.
31330038), supplemented with L-glutamine, N2 supple-
ment (Invitrogen, Cat. 17502-048), and basic recombin-
ant human Fibroblast Growth Factor (b-FGF) (Sigma,
Cat. F0291). Experiments were carried out after 4 days of
differentiation in DMEM: F12 medium containing N2
supplement, 2 ng/ml human recombinant GDNF (R&D
Systems, Cat. 212-GD), 1 mM dibutyryl cAMP (Sigma,
Cat. D0260) and 1 lg/ml tetracycline (Sigma, Cat.
87128). Cells were plated at a density of 1  105 cells/
ml (100 ll per well) and treated with soluble aggregates
in a 1:5 dilution. Lipopolysaccharide (Invivogen San
Diego, CA, Cat. Tlrl-3pelps) at 10 ng/ml was used as a
positive control and aCSF buffer in a 1:5 dilution was
used as a vehicle control. The plate was placed in an
IncuCyteV
R
S3 live cell imaging system right after treat-
ment and monitored for 48 h. Four images were taken
per well (600 cells per field of view), every hour, with
three wells per condition, totalling 7200 cells imaged
per condition per experiment. Two biological replicates
were carried out. Neurite length was measured using
NeuroTrack software with the following settings:
Segmentation Mode: Brightness; Segmentation
Adjustment: 0.7; Adjust size (pixels): 1; Min Cell Width
(lm): 25; Area (lm2) min: 500; Neurite Filtering: Best;
Neurite Sensitivity: 0.25; Neurite Width (lm): 4.
Membrane permeabilization assay
The membrane permeabilization assay was performed as
described previously.50 Briefly, liposomes composed of
16:0–18:1 PC and 18:1–12:0 biotin PC (100:1) (Avanti
Lipids), with an average diameter of 200 nm, were pre-
pared using extrusion and freeze-thaw cycles. Vesicles
filled with 100 lM Cal-520 dye were bound to a glass
surface coated with PLL-g-PEG and PLL-g-PEG biotin
(10:1) (Susos AG), via a biotin-neutravidin linkage. A ser-
ies of 9 different images were taken of 30 ll Ca2þ con-
taining buffer (L-15) alone to measure the background
for each set (Fblank). The same volume of soluble aggre-
gates (50 ll) was then incubated on the glass coverslip
for 15 min and imaged in the exact same fields of view
(Fsample). The same fields of view were then re-imaged
after the addition of 10 ll of 50 lg/ml ionomycin
(Fionomycin). By first determining the intensity of each
Table 1 Patient information
Patient ID No. Age at PM (years) PMI (h) Gender (M/F) Cause of death Braak
stage
AD1 NP17-216 77 55 F Burkitt’s Lymphoma III
AD2 NP17-194 71 70 M Pneumonia III
AD3 NP17-020 88 44 M End stage dementia III
AD, Alzheimer’s disease; F, Female; M, Male; PM, post-mortem; PMI, post-mortem interval.
Information from three Braak stage III Alzheimer’s disease patients (AD1, AD2 and AD3) whose brain tissue has been analysed in this study.
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individual vesicle, the average Ca2þ influx was calculated





Imaging was carried out using a home-built total in-
ternal reflection fluorescence (TIRF) microscope, fitted
with a 488 nm laser (Toptica, iBeam smart, 200 mW,
Munich, Germany), which was used to excite the sam-
ples. The laser beam was expanded and collimated using
two Plano-convex lenses on the back-focal plane of the
60, 1.49 NA oil immersion objective lens (APON60XO
TIRF, Olympus, product number N2709400) to a spot of
adjustable diameter. An EmCCD camera (Photometrics
Evolve, EVO-512-M-FW- 16-AC-110) was used to image
the dye fluorescence emissions collected by the objective.
Aptamer DNA-PAINT imaging
Aptamer DNA-PAINT imaging was performed as described
previously, with a few adaptations.51 Briefly, round slides
were cleaned for 1 h with argon plasma. A multiwell cham-
ber coverslip (CultureWell CWCS-50R-1.0) was then added
to the slide. The wells were cleaned with PBS 1% (v/v)
Tween 20 for 1 h before adding 5 diluted soluble aggre-
gates in PBS for 1 h. The wells were washed twice with
fresh PBS and replaced with imaging mix [2 nM imaging
strand (sequence CCAGATGTA-TCY3B), and 100 nM
aptamer-docking strand (sequence GCCTGTGGTGTTGGG-
GCGGGTGCGTTATACATCTA) in PBS]. All buffers were
passed through a 0.02lm filter (Anotop25, Whatman, Cat.
516-1501) before use. Prior to imaging, a clean coverslip
was used to seal the wells to prevent evaporation. Imaging
was performed on a home built TIRF microscope using a
1.49 N.A., 60 objective (UPLSAPO, 60X, TIRF, Olympus)
and a perfect focus system. More details about the micro-
scope set up and data analysis are described in Whiten
et al.51
Single-molecule pull-down imaging
Glass coverslips covalently mounted with polyethylene glycol
(PEG) were used for single-molecule pull-down (SiMPull)
experiments. Coverslip preparation was carried out as
described previously, with a few modifications.52 Briefly,
glass coverslips (26  76 mm, thickness 0.15 mm, Thermo
Scientific) were washed ultrasonically (cleaner USC100T,
VWR), in a series of solvents [10 min in 18.2-MX cm1
Milli-Q water, 10 min in acetone, then 10 min in methanol
(MeOH)]. The washed coverslips were then etched by 1 M
potassium hydroxide (KOH) under 20 min ultrasonication
and rinsed with a series of solvents (MeOH, 18.2-MX cm1
Milli-Q water, then MeOH). The processed coverslips were
dried using nitrogen flow and cleaned with argon plasma
for 15 min (Femto Plasma Cleaner; Diener Electronic). The
coverslips were then silanized with 5 ml of 3-aminopropyl
triethoxysilane (Fisher Scientific UK, Cat. 10677502), 8.3 ml
acetic acid (AcOH) in 166.7 ml MeOH for 20 min, with
1 min ultrasonication at the start and mid-point of reaction
(10 min after the start point). The silanized coverslips were
then rinsed in MeOH, 18.2-MX cm1 Milli-Q water, fol-
lowed by MeOH and dried using nitrogen flow. 50-well
polydimethylsiloxane (PDMS) gaskets (Sigma, GBL103250-
10EA) were then attached to the cleaned and silanized cov-
erslips. To passivate the wells, 9ml of a 100:1 aqueous mix-
ture of succinimidyl valeric acid PEG (MPEG-SVA-5000)
(110 mg ml1, Laysan Bio Inc.) and Biotin-PEG-SVA-5000
(1.1 mg ml1, Laysan Bio Inc.) were added, with additional
1ml of 1 M sodium bicarbonate (NaHCO3) (pH 8.5). The
coverslips were incubated with PEG solution overnight in a
humid chamber and then rinsed with 18.2-MX cm1 Milli-
Q water and dried with nitrogen flow. The passivated wells
were treated by adding 9ml of MS(PEG)4 methyl-PEG-NHS-
Ester (10 mg ml1, Thermo Scientific, Cat. 22341), with add-
itional 1ml of 1 M NaHCO3 (pH 8.5). The coverslips were
incubated with PEG solution overnight in a humid chamber
and then rinsed with 18.2-MX cm1 Milli-Q water and
dried with nitrogen flow. PEGylated glass coverslips were
stored in a desiccator at 20C until needed.
For the experiment, neutravidin (0.2 mg/ml) was added to
the coverslip for 5 min, followed by two wash steps with
0.05% (v/v) PBST and once with 1% (v/v) PBST.
Afterwards biotinylated 6E10 (Signet, Cat. 9340-02, 10 nM)
was added for 10 min, followed by two wash steps with
0.05% (v/v) PBST and once with 1% (v/v) PBST. The sol-
uble aggregates were added for at least 1 h at room tem-
perature followed by two wash steps with 0.05% (v/v)
PBST and once with 1% (v/v) PBST. The coverslips were
blocked using blocking solution containing 0.1% (w/v) bo-
vine serum albumin (BSA) (Thermo Scientific, Cat.
AM2616), 10% (v/v) salmon sperm (Thermo Scientific, Cat.
15632011) and 0.1% (v/v) PBST for 1 h at room tempera-
ture. The coverslips were then incubated with labelled 6E10
(cat. 80302, 500 pM) for 45 min, followed by three washing
steps with 0.05% (v/v) PBST. To properly seal the imaging
chamber and prevent evaporation, 3ll of PBS was added to
each well and sandwiched with a second coverslip.
To determine the number of fluorescent molecules in
each image, a z-stack was generated in ImageJ. The
images were cropped to 380  380 pixels and the con-
trast was adjusted. Using the negative control as a base-
line, a threshold was applied to all images, and single
molecules above this threshold were counted.
Atomic force microscopy
Samples of soluble aggregates were diluted 10 in PBS buf-
fer and imaged on freshly cleaved mica substrates using
atomic force microscopy (AFM). Ten microlitres diluted
samples were deposited on the substrate at room tempera-
ture. The samples were incubated for 10 min, followed by
rinsing with 1 ml milliQ water. The samples were then
dried using a gentle flow of nitrogen gas. AFM maps of
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3D morphology of all the samples were acquired in regime
of constant phase change, with 2–4 nm/pixel resolution
using a NX10 (Park Systems, city, South Korea) operating
in non-contact mode.53 This set up was equipped with a
silicon tip with a nominal radius of <10 nm and spring
constant of 5 N/m (PPP-NCHR). For each sample, we
scanned an area between 250 and 500 lm2. The lower
limit was used for samples where aggregated species were
found and the upper limit for the samples without aggre-
gates. Scanning Probe Image Processor (SPIP) (version 6.7.3,
Image Metrology, Denmark) software was used for image
flattening and single aggregate statistical analysis. The aver-
age level of noise for each image was measured using SPIP
software and was smaller than 0.1 nm.54 All the measure-
ments were performed at room temperature.
Statistical analysis
GraphPad Prism v9 was used to carry out statistical anal-
yses for all experimental data except for AFM data.
Unpaired two-tailed t-tests have been used to test the null
hypothesis, in cases where two independent, normally dis-
tributed samples needed comparing (liposome assay,
immunoprecipitations, and Aptamer-DNA PAINT data).
An alpha value of (P< 0.05) was chosen to represent sig-
nificant differences in the data (* ¼ P 0.05, ** ¼
P 0.01, *** ¼ P 0.001). In cases where more than
two independent variables needed comparing, a one-way
analysis of variance (ANOVA) was used (neuroinflamma-
tion, neurite length assay). This was followed by a Tukey
post hoc test when comparing the mean of each variable
to the mean of every other variable, or a Dunnett post
hoc test when comparing the mean of each variable to
the mean of one control variable. Kolmogorov–Smirnov
tests have been used when comparing non-normally dis-
tributed cumulative distributions (Aptamer-DNA PAINT
and SiMPull data). Individual statistical values are
reported in the figure legends. To assess the variability
between independent repeats of the experiment and be-
tween patients, multiple comparisons tests were carried
out (Supplementary Tables 1 and 2).
Scanning Probe Image Processor (SPIP) software was
used for image flattening and single aggregate statistical
analysis for AFM imaging data. AFM data were plotted
using OriginProV
R
2021. Mann–Whitney two-tailed tests
were used to compare the medians of the non-normally
distributed data sets. Individual statistical values are
reported in the figure legends.
Patient samples were blinded prior to experimentation
and were only unblinded after data analysis. Region se-
lection for all imaging experiments was automated, ensur-
ing randomization and elimination of human bias.
Furthermore, data analysis parameters (e.g. thresholding)
were kept consistent within each data set.
Data gathered by ELISA were analysed using MARS data
analysis software. A four-parameter logistic fit was fitted to
the data, as per the kit manufacturer’s instructions.
Data availability
Raw data were generated at the Yusuf Hamied
Department of Chemistry, University of Cambridge.
Derived data supporting the findings of this study are
available from the corresponding author on request.
Results
Characterization of soluble
aggregates using a series of
sensitive assays
A series of sensitive assays were employed to characterize
brain-derived soluble aggregates by measuring their neu-
roinflammatory potential, liposome-permeability, neuro-
toxicity, size, number and morphology (Fig. 1).
Global inflammation in the brain of
Braak stage III patients
Soluble aggregates were extracted from eight different
brain regions from three Alzheimer’s disease patients (Fig.
2A). Samples from all regions appear to be neuroinflam-
matory (Fig. 2B and C), cytotoxic (Fig. 2D) and capable
of permeabilising liposomes (Fig. 2E), to varying degrees.
This suggests that there is global pathology even at
Braak stage III. Despite patient-to-patient variability
(Supplementary Fig. 1), hippocampal aggregates appear
to be the most toxic in all three patients and have there-
fore been further characterized with our assays in com-
parison to the VAC, a region that is generally affected
later in Alzheimer’s disease progression. HPC aggregates
caused a significantly higher Ca2þ influx than VAC
aggregates (Fig. 2F), suggesting they may be better at per-
meabilizing liposomes.
Ab-containing fragments are likely
driving the soluble aggregate
inflammatory response
The solutions extracted from brain tissue are heteroge-
neous mixtures of proteins. In order to identify whether
Ab-containing fragments were involved in the inflamma-
tory response (Fig. 2B and C), an immunoprecipitation
with an APP-binding antibody (6E10) was carried out.
This enabled the treatment of BV2 cells with samples of
soluble aggregates with and without immunodepletion of
Ab-containing fragments. Samples immunodepleted of
Ab-containing fragments using the 6E10 antibody caused
a significantly lower inflammatory response than samples
that did not undergo immunodepletion (Fig. 3A, B and
Supplementary Fig. 2). These data are consistent with Ab
aggregates being involved in neuroinflammation.
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Soluble aggregates cause neurite
retraction in human LUHMES
neurons
Treatment of LUHMES cells with HPC and VAC soluble
aggregates caused significant neurite retraction over 48 h
(Fig. 4A–C and Supplementary Fig. 3). This suggests that
the soluble aggregates are neurotoxic, similar to what has
been previously reported with Braak stage VI soluble
aggregates.23 Surprisingly, there was no significant differ-
ence between the level of HPC and VAC aggregate-
induced neurite retraction (Fig. 4D).
Figure 2 Inflammation and liposome data. (A) Diagram of the eight regions that were removed, soaked, and used for experimentation.
(B) TNF-a response from BV2 cells treated with soluble aggregates (diluted 1:5) from eight different brain regions. Each point represents an
average from three different Alzheimer’s disease patients. Vehicle control was aCSF at equal volume to soluble aggregates. Lipopolysaccharide
at 10 ng/ml was used as a positive control (not shown). Connecting lines have been added for visual clarity. Error bars are mean 6 SD.
Individual patient data can be found in Supplementary Fig. 1. (C) TNF-a measurements from the 96-h time point of the inflammation assay.
Each point represents one of the three Alzheimer’s disease patients. Error bars are mean 6 SD. Statistical analysis has been carried out
relative to the Vehicle control [one-way ANOVA: F(8,18) ¼ 5.989, P < 0.001. Post hoc Dunnett test against Vehicle: HPC: P < 0.001; CBL: P ¼
0.008; VAC: P ¼ 0.02; PP: P ¼ 0.46; AC: P ¼ 0.62; PVC: P ¼ 0.64; FC: P ¼ 0.69; EC: P ¼ 0.74]. (D) Cell viability was assessed from cell
supernatant from the 96-h time point of the inflammation assay using an LDH assay. Each point represents one of three Alzheimer’s disease
patients. Error bars are mean 6 SD. (E) Ca2þ influx of each patient and region measured by liposome assay. Error bars are mean 6 SD of
fields of view. HPC and VAC samples have been repeated in an independent experiment and show a similar trend. (F) Ca2þ influx from two
repeat experiments, averaged by brain region (HPC and VAC). Each point represents one of three Alzheimer’s patients. Error bars are mean
6 SD (HPC vs VAC: n ¼ 3, P ¼ 0.007, t4 ¼ 5.201). AC, anterior cingulate cortex; CBL, cerebellum; EC, entorhinal cortex; FC, frontal cortex;
HPC, hippocampus; PP, posterior parahippocampal gyrus, PVC, primary visual cortex; TNF-a, tumour necrosis factor-a; VAC, visual
association cortex.




The size and number of the soluble aggregates have been
characterized by Aptamer DNA-PAINT super-resolution
microscopy. This was performed using an aptamer that
binds to fibrillar Ab, although it can also bind fibrillary
a-synuclein fibrils. The aggregates vary from region to re-
gion, and from patient to patient. In all cases, there is a
variety of soluble aggregates of a range of lengths
detected, however the length distributions differ (Fig. 5A
and C). The HPC aggregates appear to be shorter than
VAC aggregates in general, and have a smaller propor-
tion of longer aggregates (over 100 nm) (Fig. 5B and D).
Despite the clear difference in length there is a relatively
small difference between the inflammatory responses of
these two regions (Fig. 2B), suggesting that the aggregates




The 3D morphology and the heterogeneity of the aggre-
gates from the HPC and VAC samples were character-
ized using high-resolution and phase-controlled AFM
imaging (Fig. 6A and B).53–55 In both the HPC and the
VAC samples, we observed the abundant presence of
spherical aggregates. The single molecule statistical ana-
lysis of the cross-sectional diameter of these aggregates
showed that the spherical aggregates present in the HPC
samples had a diameter (30–50 nm) that was signifi-
cantly smaller than the diameter of the spherical
aggregates in the VAC samples (50–80 nm) (Fig. 6C).
The difference of the average diameter of the aggregates
is in agreement with the results obtained by Aptamer
DNA-PAINT in Fig. 5.
Furthermore, we observed that HPC samples contained
several elongated toroidal structures, as well as fibrillar
and prefibrillar aggregates. The VAC samples contained a
significantly smaller number of elongated aggregates, and
toroidal aggregates were not found in the 500 lm2 area
of the sample that was imaged in a randomized manner.
The statistically significant difference in the number of
elongated aggregates in the HPC versus VAC samples
was evaluated by calculating the density of the number
of these elongated aggregates per lm2 (Fig. 6D). The tor-
oidal and fibrillar aggregates had an average length of
100 nm (Fig. 6E).
AFM cannot determine the proteins the toroidal, fibril-
lar and spherical structures consist of. However, the dif-
ferent heterogeneity of the aggregated species in the HPC
and VAC samples suggests that there is a regional vari-
ability in the structures of soluble aggregates, and toroid-





Aptamer DNA-PAINT and AFM imaging allowed us to
characterize the morphology, size, number and shape of
the soluble aggregates. However, as the techniques are
not protein-specific, the SiMPull technique was
employed to specifically characterize the Ab-containing
Figure 3 Immunodepletion of Ab-containing fragments. (A) TNF-a response measured from BV2 cells treated with soluble
aggregates that have either undergone (red) or not undergone (blue) a pull-down using a 6E10 APP-binding antibody. Each point represents an
average from three patients. Vehicle control was aCSF at equal volume to soluble aggregate samples. Lipopolysaccharide at 10 ng/ml was used
as positive control (not shown). Error bars are mean 6 SD. (B) TNF-a measured at the 96-h time point. Each point represents one of three
Alzheimer’s disease patients. Error bars are mean 6 SD (Unpaired two-tailed t-test, HPC vs HPC þ 6E10: n ¼ 3, P ¼ 0.04, t4 ¼ 3.061; VAC vs
VAC þ 6E10: n ¼ 3, P ¼ 0.002, t4 ¼7.658). Individual patient data can be found in Supplementary Fig. 2.
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aggregates in these samples.56 Intensity values provide
an approximation of aggregate molecular weight, assum-
ing that more fluorescent antibodies bind larger aggre-
gates, and hence an increase in intensity correlates with
an increase in aggregate size. The intensity values sug-
gest that VAC samples contain larger Ab-containing
aggregates than the HPC samples in two out of the
three patients (Fig. 7A–C), and when averaging the three
patients (Fig. 7D). This is in agreement with the
Aptamer DNA-PAINT and AFM data, which also show
that VAC samples have larger aggregates than HPC
samples. There was no significant difference in the num-
ber of detectable spots per field of view for the two
regions (Fig. 7E).
Figure 4 Neurite length. Representative images of neurite length of LUHMES cells treated with(A) aCSF buffer and (B) HPC at 0 and 48-h
time points. Representative images of LUHMES cells treated with HPC and VAC from all three Alzheimer’s disease patients can be found in
Supplementary Fig. 3. (C) Relative neurite length of LUHMES cells (7200 cells imaged per condition) treated with soluble aggregates at a 1:5
dilution for 48 h, normalized to neurite length at the 0-h time point (1.0), and vincristine at 48 h (0) to signify total neurite retraction. Vehicle
was aCSF at same dilution as soluble aggregates (1:5), and vincristine (50 nM) served as a positive control for neurite retraction. Error bars
are mean 6 SD from two biological repeats, with each condition carried out in triplicate wells, and 4 images analysed per well. (D) Relative
neurite length at the 48-h time point averaged by brain region. Each point represents one of three Alzheimer’s disease patients. Error bars are
mean 6 SD [One-way ANOVA: F(2,5) ¼ 18.63, P ¼ 0.005. Post hoc Tukey test: n ¼ 3 for all: Vehicle vs HPC: P ¼ 0.008; Vehicle vs VAC: P ¼
0.005; HPC vs VAC: P ¼ 0.84].
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Discussion
The only previous study using soluble aggregates
extracted from soaking brain tissue analysed Braak stage
VI Alzheimer’s disease brains and showed that the major
species was Ab that caused long-term potentiation deficit
and neuronal retraction.23 In this pilot study, we wanted
to first see whether we could detect any aggregates in
early disease soluble aggregates, since this would allow us
to study earlier events in disease development. We char-
acterized the soluble aggregates from eight different brain
regions from three Alzheimer’s disease patients at Braak
stage III. Soluble aggregates from all eight regions were
neuroinflammatory and liposome-permeable, to varying
degrees. This suggests that there is global pathology
occurring even at Braak stage III, which is an early stage
of disease. We found extensive variation between the
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Figure 5 Length and number characterization of soluble aggregates using Aptamer DNA-PAINT. (A) Cumulative frequency of
soluble aggregates in all eight brain regions and in (B) HPC and VAC regions only, from three independent experiments (Kolmogorov–
Smirnov test, AD1: P < 0.001, D ¼ 0.2092; AD2: P ¼ 0.03, D ¼ 0.0974; AD3: P < 0.001, D ¼ 0.3799; Average: P < 0.001, D ¼ 0.2016). See
Supplementary Table 1 for the results of multiple comparison test. (C) Proportion of soluble aggregates over 100 nm in length in all eight
brain regions and in (D) HPC and VAC regions only. Each point in the AD1, AD2 and AD3 graphs represents one of three replicates; each
point in the Average graph represents one of three Alzheimer’s disease patients. Error bars are mean 6 SD. (Unpaired two-tailed t-test, n ¼ 3
for all. AD1: P < 0.001, t4 ¼ 16.71; AD2: P ¼ 0.21, t4 ¼ 1.510; AD3: P ¼ 0.002, t4 ¼ 7.618; Average: P < 0.001, t4 ¼ 10.66). (E)
Representative super-resolved images of aggregates in HPC and VAC samples.
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aggregate length and number, but clear differences be-
tween HPC and VAC, since the former is affected very
early in Alzheimer’s disease and the latter is largely un-
affected until late disease. We therefore chose to compare
the soluble aggregates in HPC and VAC regions using all
assays, with VAC serving as an internal control for each
patient.
Despite patient-to-patient variability, HPC aggregates
appeared to be the most toxic. TNF-a secretion in re-
sponse to soluble Ab aggregates has been previously
Figure 6 High-resolution AFM imaging of aggregates 3D morphology. Structural characterization of the aggregates in (A) HPC and
(B) VAC regions using AFM. The blue arrows are highlighting toroidal and elongated aggregates. (C) The single aggregate statistical analysis of
the cross-sectional diameter of the spherical aggregates reveals that VAC spherical aggregates are significantly larger than HPC ones (Mann–
Whitney test, two-tailed; HPC1 vs VAC1: P < 0.001, U ¼ 140761; HPC2 vs VAC2: P < 0.001, U ¼ 56141; HPC3 vs VAC3: P < 0.001, U ¼
125376). (D) Bar plot with SD of the density of the number of elongated protofilaments and toroidal oligomers per lm2 in each sample. The
graph shows the significant presence of elongated aggregates in the HPC (n1¼35, n2¼17, n3¼16 per 2020 lm2) compared to the VAC
samples (n1 ¼ 2, n2 ¼ 0, n3 ¼ 1 per 2020 lm2) (Unpaired two-tailed t-test, HPC1 vs VAC1: P ¼ 0.03, t35 ¼ 2.195; HPC3 vs VAC3: P ¼ 0.02,
t15 ¼ 2.706). (E) Statistical analysis of the cross-sectional length of the toroidal, prefibrillar and fibrillar aggregates. (F) Statistical analysis of
the cross-sectional height of the toroidal, prefibrillar and fibrillar aggregates.
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reported to cause long-term potentiation deficit,57 a cellu-
lar correlate of memory loss, so together with our data
showing inflammation being highest in the HPC, this
offers an explanation as to why memory loss occurs in
Alzheimer’s disease.
We have identified the size, length, morphology and
number of these endogenous soluble aggregates. These
varied from region to region and from patient to patient
but importantly there was a range of aggregates of differ-
ent sizes (20–200 nm) in all regions. It should be noted
that the aptamer used for the Aptamer DNA-PAINT
studies can bind both Ab and a-synuclein, however, our
work7,40 and previous work23 suggests that it is most
likely Ab. Furthermore, AFM imaging is not protein spe-
cific, but the sizes of the imaged aggregates are consistent
with those measured with Aptamer DNA-PAINT, similar
to what was observed in our previous work on CSF.40
We have taken advantage of the high-resolution of
AFM to further characterize the morphology and struc-
ture of soluble aggregates from the HPC and the VAC.
HPC samples contained structures of toroidal nature, as
well as fibrillar structures. VAC samples rarely had fibril-
lar structures and contained many spherical structures.
We have found in CSF41 and with synthetic aggregates7
that protofibrils are the main inflammatory species. This
is because they are the right diameter to be bound by
multiple toll-like receptor 4s (TLR4s). Indeed, in the HPC
samples about 7–15% of the aggregates detected by
AFM have the right height (2 nm) to produce a strong
inflammatory response, compared to the proportion in
the VAC, which is less than 2%. These aggregates were
less than 100 nm in length, which is also consistent with
our observation, combining our Aptamer DNA-PAINT
and inflammatory assay results, that the inflammatory
aggregates are less than 100 nm in length. Overall, our
data suggest that fibrillary aggregates less than 100 nm in
length and 2 nm in diameter can cause inflammation and
that there are more of these aggregates in the HPC com-
pared to the VAC.
A previous study has found that activated microglia are
present in HPC and VAC in Alzheimer’s disease patients
classed as having low neuropathologic change.10 Both the
HPC and VAC already had some activated microglia. It
was found that there are more microglia and more acti-
vated microglia in HPC than VAC, but an increase in the
proportion of activated microglia occurred in both areas
at early stages. This is supported by cross-sectional stud-
ies, which have used PET scans to detect activated micro-
glia, and have shown increases in inflammation in early
disease all over the brain that is associated with cognitive
Figure 7 Single-molecule pull-down characterization of Ab-containing fragments in samples. Cumulative frequency plots of
intensity values of Ab aggregates in HPC and VAC samples from (A) AD1 (Kolmogorov–Smirnov test, HPC vs VAC, P < 0.001, D ¼ 0.1987),
(B) AD2 (Kolmogorov–Smirnov test, HPC vs VAC, P < 0.001, D ¼ 0.1451), (C) AD3 (Kolmogorov–Smirnov test, HPC vs VAC, P < 0.001, D
¼ 0.0804) and (D) Average of the three patients (Kolmogorov–Smirnov test, HPC vs VAC, P < 0.001, D ¼ 0.05452). See Supplementary
Table 2 for results of multiple comparison test. (E) The number of detected spots (Ab) per field of view (380 x 380 pixel cropped images).
Each point represents one of three Alzheimer’s disease patients. Error bars are mean 6 SD (Unpaired two-tailed t-test, HPC vs VAC, n ¼ 3, P
¼ 0.47, t4 ¼ 0.7978).
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decline.58–60 Peripheral cytokine studies have shown that
this increase in inflammation in early disease plateaus in
later stages of the disease.61–64 Furthermore, recent stud-
ies have shown that microglia do not appear to take up
and transport soluble Ab, but instead degrade them by
secreting insulin-degrading enzyme (IDE).65 In combin-
ation with our work, this suggests that instead of aggre-
gates spreading through the brain, the same aggregate-
induced inflammation is occurring locally to a greater or
lesser extent in the entire brain simultaneously.
It should be noted that our study was intended to de-
termine the feasibility of this approach and has been per-
formed on a small number of Alzheimer’s disease patients
due to the manual nature of these experiments. We are
working on automating these assays to allow for more
high-throughput assessment of Alzheimer’s disease brain
tissue, to explore whether similar characteristics of sol-
uble aggregates are found in larger cohorts and allow
comparison to age matched control brain and brain at
later stages of AD. More sensitive neuroinflammation
assays are also needed to better characterize the inflam-
matory properties of aggregates from different brain
regions. In the future, this approach has the potential to
characterize the aggregates that form in humans during
the development of AD and identify which aggregates are
toxic and by what mechanisms. In particular, by studying
regions where inflammatory aggregates are just starting
to be formed, it may be possible to study the early proc-
esses of disease.
Overall, our data are consistent with small soluble Ab-
containing aggregates, 2 nm in diameter and less than
100 nm in length, driving inflammation in Alzheimer’s
disease to greater or lesser extents in all regions of the
brain and this aggregate-induced inflammation then caus-
ing cellular dysfunction and ultimately cell death. Our
study also highlights the heterogeneity in size, morph-
ology and structure of the aggregates formed in the brain
with the proportion of different aggregates differing be-
tween brain regions. It also highlights the challenges in
selectively targeting the correct species and suggests that
targeting the aggregate induced inflammation may be a
better therapeutic strategy than attempting to target spe-
cific aggregates.
Supplementary material
Supplementary material is available at Brain
Communications online.
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